Filing Flows › Amgen (AMGN) › Q3 2026 › vs Q2 2026
Amgen (AMGN) Q3 2026 vs Q2 2026 (quarter over quarter)
Amgen's revenue rose $311M (+3%) from $10.1B in Q2 2026 to $10.4B in Q3 2026. Operating margin 35.8% against 35.0% (+0.8 pts).
Amgen, Q3 2026: revenue $10.4B (+8% year over year), operating margin 35.8%, net earnings $3.9B, operating cash flow $4.2B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 35.8% | 35.0% | +0.8 pts |
| Net margin | 37.3% | 23.6% | +13.7 pts |
| Free cash flow margin | 35.3% | 34.7% | +0.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $10.4B | $10.1B | $311M | +3% |
| Other income, net | $976M | −$746M | $1.7B | — |
| Operating profit | $3.7B | $3.5B | $196M | +6% |
| Costs & expenses | $6.7B | $6.5B | $115M | +2% |
| Pre-tax earnings | $4.7B | $2.8B | $1.9B | +69% |
| Cost of revenue | $2.8B | $2.8B | −$23.0M | -0.8% |
| Research & development | $2.1B | $1.9B | $243M | +13% |
| SG&A | $1.7B | $1.7B | −$65.0M | -4% |
| Other operating costs | $76.0M | $116M | −$40.0M | -34% |
| Net earnings | $3.9B | $2.4B | $1.5B | +63% |
| Income tax | $822M | $393M | $429M | +109% |
| Depreciation & amortization | $1.1B | $1.1B | $10.0M | +0.9% |
| Share-based compensation | $128M | $165M | −$37.0M | -22% |
| Working capital & other | $873M | −$350M | $1.2B | — |
| Operating cash flow | $4.2B | $4.0B | $239M | +6% |
| Free cash flow (OCF − capex) | $3.7B | $3.5B | $165M | +5% |
| Capital expenditures | $587M | $513M | $74.0M | +14% |
Questions
How much did Amgen's revenue grow quarter over quarter in Q3 2026?
Amgen's revenue rose $311M (+3%) from $10.1B in Q2 2026 to $10.4B in Q3 2026. Operating margin 35.8% against 35.0% (+0.8 pts).